ABC Heart Fail Cardiomyop 2021; 1(2): 90-94
Cardiac Amyloidosis and Aortic Stenosis: When to Consider it and How to Treat it?
Marcelo Kirschbaum, Aristóteles Conte Alencar Neto, Vitor Emer de Egypto Rosa, Félix José Alvarez Ramires, Alexandre Antonio Cunha Abizaid, Fábio Sandoli de Brito Junior, Flávio Tarasoutchi, Roberto Kalil Filho, Fábio Fernandes
Abstract
Aortic stenosis is the most prevalent valve disease in clinical practice. The wild form of transthyretin amyloidosis has an increased incidence in elderly individuals, usually over 70 years of age. Amyloidosis and aortic stenosis are 2 diseases that affect similar populations; therefore, they may coexist in the same patient.
Patients with amyloidosis and aortic stenosis have disproportionately higher serum levels of troponin and NT-proBNP compared to patients with pure severe aortic stenosis in addition to greater ventricular hypertrophy. Therapeutic decisions for these patients must be individualized and promptly discussed by the heart team. In this article, we discuss this association and possible valve therapies, in addition to the possibility of specific treatment for amyloidosis.
649
